First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

In the Phase III INPULSIS(®) trials, 52 weeks’ treatment with nintedanib reduced decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS(®) trials could receive nintedanib in an open-label extension trial (INPULS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuyts, Wim A., Kolb, Martin, Stowasser, Susanne, Stansen, Wibke, Huggins, John T., Raghu, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031742/
https://www.ncbi.nlm.nih.gov/pubmed/27377558
http://dx.doi.org/10.1007/s00408-016-9912-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031742/
https://www.ncbi.nlm.nih.gov/pubmed/27377558
http://dx.doi.org/10.1007/s00408-016-9912-1

Ejemplares similares